• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Resolution of severe pyoderma gangrenosum in a patient with streaking leukocyte factor disease after treatment with tacrolimus (FK 506).

作者信息

Abu-Elmagd K, Van Thiel D H, Jegasothy B V, Jacobs J C, Carroll P, Rodriquez-Rilo H, Ackerman C D, Fung J J, Starzl T E

机构信息

Pittsburgh Transplant Institute, Pennsylvania.

出版信息

Ann Intern Med. 1993 Oct 1;119(7 Pt 1):595-8. doi: 10.7326/0003-4819-119-7_part_1-199310010-00008.

DOI:10.7326/0003-4819-119-7_part_1-199310010-00008
PMID:7689802
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3091479/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0a8/3091479/bc8796ff6186/nihms-245751-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0a8/3091479/bc8796ff6186/nihms-245751-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0a8/3091479/bc8796ff6186/nihms-245751-f0001.jpg

相似文献

1
Resolution of severe pyoderma gangrenosum in a patient with streaking leukocyte factor disease after treatment with tacrolimus (FK 506).一名线状白细胞因子病患者在接受他克莫司（FK 506）治疗后严重坏疽性脓皮病的消退。
Ann Intern Med. 1993 Oct 1;119(7 Pt 1):595-8. doi: 10.7326/0003-4819-119-7_part_1-199310010-00008.
2
Resolution of pyoderma gangrenosum using tacolimus (FK-506).使用他克莫司（FK - 506）治疗坏疽性脓皮病取得缓解。
Aust N Z J Med. 1996 Apr;26(2):238-9. doi: 10.1111/j.1445-5994.1996.tb00896.x.
3
Topical tacrolimus (FK 506) is effective in the treatment of pyoderma gangrenosum.外用他克莫司（FK 506）治疗坏疽性脓皮病有效。
J Am Acad Dermatol. 2000 Feb;42(2 Pt 1):304-5. doi: 10.1016/s0190-9622(00)90149-x.
4
Efficacy of tacrolimus (FK 506) in idiopathic treatment-resistant pyoderma gangrenosum.
J Am Acad Dermatol. 1998 Oct;39(4 Pt 1):648-50. doi: 10.1016/s0190-9622(98)70020-9.
5
Pyoderma gangrenosum in an infant: A case report and review of the literature.婴儿坏疽性脓皮病：一例病例报告及文献综述
Pediatr Dermatol. 2018 Sep;35(5):e257-e261. doi: 10.1111/pde.13471. Epub 2018 Apr 15.
6
Tacrolimus to treat pyoderma gangrenosum resistant to cyclosporine.他克莫司治疗对环孢素耐药的坏疽性脓皮病。
Ann Intern Med. 1998 May 1;128(9):783-4. doi: 10.7326/0003-4819-128-9-199805010-00031.
7
Topical tacrolimus for pyoderma gangrenosum.
Br J Dermatol. 1998 Oct;139(4):755-7. doi: 10.1046/j.1365-2133.1998.02491.x.
8
Successful therapy of refractory pyoderma gangrenosum and periorbital phlegmona with tacrolimus (FK506) in ulcerative colitis.
Inflamm Bowel Dis. 2004 Jul;10(4):421-4. doi: 10.1097/00054725-200407000-00014.
9
Successful topical tacrolimus (FK506) therapy in a child with pyoderma gangrenosum.外用他克莫司（FK506）成功治疗一名儿童坏疽性脓皮病。
J Pediatr Gastroenterol Nutr. 2002 May;34(5):555-7. doi: 10.1097/00005176-200205000-00015.
10
Recalcitrant pyoderma gangrenosum treated with systemic tacrolimus.
Br J Dermatol. 1999 Mar;140(3):562-4. doi: 10.1046/j.1365-2133.1999.02745.x.

引用本文的文献

1
Clinical and Genetic Findings of the First Report of PAPA Syndrome in Brazil.巴西首例PAPA综合征报告的临床及遗传学发现
Case Reports Immunol. 2021 Dec 13;2021:6660937. doi: 10.1155/2021/6660937. eCollection 2021.
2
Pyoderma gangrenosum: From historical perspectives to emerging investigations.坏疽性脓皮病：从历史视角到新兴研究。
Int Wound J. 2020 Oct;17(5):1255-1265. doi: 10.1111/iwj.13389. Epub 2020 May 6.
3
Brief report: genotype, phenotype, and clinical course in five patients with PAPA syndrome (pyogenic sterile arthritis, pyoderma gangrenosum, and acne).

本文引用的文献

1
The in vitro action of hydrocortisone on leucocyte migration.氢化可的松对白细胞游走的体外作用。
J Exp Med. 1958 Feb 1;107(2):211-8. doi: 10.1084/jem.107.2.211.
2
The chemosuppression of chemotaxis.趋化性的化学抑制
J Exp Med. 1966 Aug 1;124(2):209-26. doi: 10.1084/jem.124.2.209.
3
Effects of tetracycline on leukotaxis.
J Infect Dis. 1974 Feb;129(2):110-6. doi: 10.1093/infdis/129.2.110.
简短报告：5例PAPA综合征（化脓性无菌性关节炎、坏疽性脓皮病和痤疮）患者的基因型、表型及临床病程
Arthritis Rheum. 2012 Jun;64(6):2022-7. doi: 10.1002/art.34332. Epub 2011 Dec 12.
4
[Management of pyoderma gangrenosum. An update on clinical features, diagnosis and therapy].[坏疽性脓皮病的管理。临床特征、诊断和治疗的最新进展]
Hautarzt. 2010 Apr;61(4):345-53; quiz 354-5. doi: 10.1007/s00105-009-1909-8.
4
FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro.FK-506，一种从链霉菌中分离出的新型免疫抑制剂。II. FK-506的体外免疫抑制作用。
J Antibiot (Tokyo). 1987 Sep;40(9):1256-65. doi: 10.7164/antibiotics.40.1256.
5
FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics.FK-506，一种从链霉菌中分离出的新型免疫抑制剂。I. 发酵、分离以及物理化学和生物学特性。
J Antibiot (Tokyo). 1987 Sep;40(9):1249-55. doi: 10.7164/antibiotics.40.1249.
6
A highly sensitive method to assay FK-506 levels in plasma.一种检测血浆中FK-506水平的高灵敏度方法。
Transplant Proc. 1987 Oct;19(5 Suppl 6):23-9.
7
Pyoderma gangrenosum in infancy: the youngest reported patient.婴儿期坏疽性脓皮病：报告的最年幼患者
J Am Acad Dermatol. 1991 Jul;25(1 Pt 1):109-10. doi: 10.1016/s0190-9622(08)80497-5.
8
Efficacy of FK 506 in the treatment of recalcitrant pyoderma gangrenosum.FK506治疗顽固性坏疽性脓皮病的疗效
Transplant Proc. 1991 Dec;23(6):3328-9.
9
Adverse effects associated with the use of FK 506.与使用FK 506相关的不良反应。
Transplant Proc. 1991 Dec;23(6):3105-8.
10
FK506 and pertussis toxin distinguish growth-induced locomotor activation from attractant-stimulated locomotion in human blood lymphocytes.FK506和百日咳毒素可区分人血淋巴细胞中生长诱导的运动激活与趋化剂刺激的运动。
Immunology. 1990 Nov;71(3):417-22.